CoreAge Rx vs VevaRX

The verdict for women

CoreAge Rx edges out VevaRX on the Metabolic-Fit Score, 86 to 31 (B vs C). Someone considering both compounded injection options who wants an advertised flat price without a required subscription and will confirm the exact prescription, state access and refund terms.

VevaRX is still a genuine option — its own semaglutide page gives two different prices for the same product. The pricing cards read $189 a month or $399 for three months, and the paragraph directly beneath them reads $167 a month or $467 for three — and since $467 is the tirzepatide total, the text appears to be leftover copy from the other product. The tirzepatide page has an arithmetic problem of its own, advertising $467 as equivalent to $149 a month when three months at $467 is $155.67, and there is no monthly tirzepatide plan at all: a three-month minimum applies and the plan renews every three months. The terms then compound it by referring repeatedly to a different company's website and listing prices that match nothing on the product pages. What is genuinely strong is easy to miss underneath all that. VevaRX enumerates thirty-six states by name rather than claiming fifty, it locks the price before intake and holds it at every dose, and the quoted figure includes the provider visit, the supplies and free two-to-three-day shipping. Weigh the six women's-health factors below against your own priorities.